WXIBF Stock, Wuxi Biologics Cayman Inc Information

WuXi Biologics is a contract development and manufacturing organization, or CDMO, for biologic drugs. It was founded in 2010 as part of WuXi AppTec and listed on the Hong Kong Stock Exchange in 2017. WuXi provides comprehensive services from conception to commercialization, including drug discovery, clinical and commercial manufacturing, and various support services such as process validation, viral clearance studies, product and cell line characterization, stability studies, and others. It does not conduct clinical trials.